Vision &


Our vision

Our vision is to build a leading portfolio of critical medicines that improves the standard of care for more patients around the world.

Our strategy

We capitalize on our leading position to further develop our Critical Care portfolio internationally while also leveraging existing portfolio and capabilities to scale up the Rare Diseases franchise.

We do this via our three growth strategies:

  • Commercial Excellence

    Deliver development initiatives, increase penetration and maintain leadership

  • Smart R&D

    Develop a unique pipeline of R&D projects focusing on high unmet medical needs

  • M&A Engine

    Execute targeted and highly selective M&A

These are underpinned by our focus on sustaining operational excellence and strengthening the organisation.

  • “SERB is a global, fully integrated pharmaceutical platform with expertise in complex niche products.  We have a diverse portfolio in critical care and rare diseases, and unique know-how and biologic manufacturing capabilities.

    Arthur Pignot, Chief Strategy Officer

Interested in joining us?

We’re always on the lookout for talented, passionate people who share our values and exhibit the behaviours that make working here different.

You are leaving the global corporate website
This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
Choose your region